Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71475 | 1.00 | HSD17B10 (0.34) | HSD17B10HPGDSMN1; SMN2ALDH1A1BTK | |
| SCHEMBL72241 | 0.80 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL9934981 | 0.80 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL72711 | 0.77 | ALDH1A1 (0.46) | HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL72710 | 0.77 | ALDH1A1 (0.46) | HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL71822 | 0.77 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL73427 | 0.77 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL71821 | 0.77 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL88243 | 0.76 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL88242 | 0.76 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1961750-A1 | VLA-4 INHIBITORY DRUG | Daiichi Sankyo Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | HSD17B10 651/4885HPGD 1752/4885SMN1; SMN2 4739/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | HSD17B10 861/4885HPGD 1734/4885SMN1; SMN2 4702/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | HSD17B10 736/4885HPGD 2201/4885SMN1; SMN2 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.